Analysts expect this medical device company to grow by more than 75% next year.
Zynex, Inc. (ZYXI)
From Weiss Ultimate Portfolio
The ADP National Employment Report showed that private employers added just 167,000 jobs in July, way below the 1.5 million Wall Street was expecting. Clearly, our country is not creating new jobs at a meaningful level. If the coronavirus infections continue to grow, even more businesses are going to shut down, making the jobs situation even worse.
And the situation for businesses that manage to stay open isn’t so pretty either. So far, 75% of companies in the S&P 500 have reported Q2 results. The average drop in revenues is 12.8% and the average decline in profits is a mind-numbing 48%.
Some industries are doing better (and worse) than others. Here’s how the 11 industry categories have fared:
• Technology: +0.4%
• Consumer Staples: -0.6%
• Health Care: -1%
• Utilities: -2%
• Communications: -8%
• Financials: -10%
• Real Estate: -11%
• Materials: -16%
• Consumer Discretionary: -22%
• Industrials: -29%
• Energy: -40%
No question—our economy has morphed into a tale of “haves” and “have-nots.” And one of the biggest “haves” in this market is health care, which is why I am recommending Zynex Inc. (Rated “B”)
One of my best friends in the world has rheumatoid arthritis and has suffered from chronic pain for years. The only medication that gave her pain relief were opioids, but they left her in a fog that inhibited her daily life. In fact, her physician was so concerned about the safety of opioids that he would only write smaller prescription. The consequence is my friend would run out of pills and be close to incapacitated by pain until she could get a refill.
This all changed when she got an electrotherapy device known as “NexWave” from Zynex. This product completely changed her life.
Just take a look at some of the incredible highlights of the product:
Zynex has developed an electronic-stimulus device that is used for management of chronic pain. Unlike opioids, NexWave doesn’t have the risk of deadly side-effects.
In addition to this product, Zynex has invented other innovative, non-invasive electrotherapy devices that are used by people who suffer from chronic pain. Electrotherapy has proven to be an effective pain reduction treatment.
One out of three Americans experience persistent chronic pain at some time throughout their lives, and the loud outcry against opioids has sent Zynex’s business to the moon.
Order growth was a stunning 87% in Q2, and this would have been even better if not for the impact of the coronavirus pandemic, which has made in-person sales calls to medical clinics impossible.
In the most recent quarter, revenue jumped to $19.26 million—an 87% year-over-year increase, which beat forecasts of $19.12 million—and profits surged by 50% to 9 cents per share.
The reason for the monster growth, despite the coronavirus shutdown that made it impossible to visit medical offices, was Zynex’s genius business strategy to rent—not sell—its medical devices on a subscription basis.
People with chronic pain, like my friend, are no way going to give up on a solution to their pain. Once a patient signs up and enjoys comfortable pain relief, they’re a customer for life.
Tony Sagami, Weiss Ultimate Portfolio, 1-877-934-7778, weissratings.com, August 7, 2020